Incyte Genomics Inc

Day range

$112.75 – $115.93

Open

$115.49

Prev close

$115.71

Volume

1.19M

Market cap

$23.45B

Shares out

202.7M

P/E

14.55

P/S

4.03

P/B

3.70

P/FCF

12.21

ROE

25.4%

ROA

20.5%

Debt/Equity

0.01

Div yield

0.00%

As of Oct 23, 2026

• Settlement agreementJun 22, 2026

  Incyte Corporation (the "Company") today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services ("CMS") to resolve the Company's litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi® (ruxolitinib), and the Company has withdrawn its lawsuit challenging the regulations.

• Acquisition agreementJun 8, 2026

  On June 8, 2026, Incyte Corporation (the "Company") issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC ("Vega Therapeutics").

• Director departureMar 30, 2026

  On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the "Company") that she was resigning from the Company's Board of Directors (the "Board"), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company's Board since 2022, was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Executive officer appointmentMar 26, 2026

  Pablo J. Cagnoni's title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein's title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa's title was changed to Executive Vice President and Head of U.S. Commercial.

• Clinical trial resultsMar 6, 2026

  The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial announced in December 2024.

• ABBVABBVIE INC.+0.29%

Days to cover

6.1

Short interest

9.99M

Avg volume

1.65M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• INCY or TECH: Which Is the Better Value Stock Right Now?
  positiveZacks Investment Research· Sep 30, 2026
• Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
  positiveBenzinga· Jun 9, 2026
• China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
  neutralGlobeNewswire Inc.· Sep 28, 2025
• Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight
  positiveGlobeNewswire Inc.· May 27, 2025
• Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités
  positiveGlobeNewswire Inc.· May 9, 2025